Eli Lilly raises earnings outlook as obesity drug demand drives strong growth, UBS says
Eli Lilly (LLY) reported strong Q3 results, beating revenue estimates by $2B and raising full-year guidance by $5B, driven by high demand for obesity and diabetes drugs. UBS cites 30% revenue growth despite price declines, forecasts $110B revenue and $53 EPS by 2027, and raised its price target to $1,625.
How this was made
The 30-second read
Why it matters
The guidance raise could trigger a re‑rating by other analysts and increase target prices.
Market read
Guidance upgrade for a mega‑cap pharma is a high‑impact catalyst for the stock and its sector.
What to watch
Potential regulatory scrutiny of obesity drugs and the pace of Medicare bridge enrollment.
Background
Eli Lilly reported a Q3 beat and UBS upgraded its outlook, citing strong volume growth in obesity and diabetes drugs.
Ticker impact
UBS raised Eli Lilly's full-year revenue guidance by $5 billion and its 2027 EPS estimate to $53, indicating stronger earnings outlook.
likely upward pressure as investors price in stronger guidance
Guidance lifts are material for a large‑cap pharma and typically trigger buying pressure.
Market effects
May boost sentiment for the broader biotech and obesity‑drug space.
Positive for U.S. pharma stocks and could lift related ADRs.
Highlights growing demand for obesity treatments worldwide.
Counterpoint
If pricing pressure intensifies or generic competition accelerates, the guidance may be overly optimistic.
Key entities
- companyEli Lilly and Co
Pharmaceutical manufacturer
- analystUBS
Investment bank providing the earnings outlook
